Comparison
3 Methylglutaconic Aciduria Type 2 C0574083 vs 3m Syndrome 2 C2752041
Clinical comparison between 3 Methylglutaconic Aciduria Type 2 and 3M Syndrome 2 for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria Type 2 C0574083
Also called Barth syndrome, this genetic condition primarily affects males and impairs mitochondrial function. It causes heart muscle weakness, muscle weakness, and recurrent infections. Treatment includes cardiac care, infection prevention, and supportive therapies.
3m Syndrome 2 C2752041
A rare genetic disorder causing severe short stature with characteristic facial features and skeletal changes. Management involves growth monitoring and supportive orthopedic care.
6 comparison axes
Onset
3 Methylglutaconic Aciduria Type 2 C0574083
0-5
3m Syndrome 2 C2752041
0-0
Onset patterns differ
Severity
3 Methylglutaconic Aciduria Type 2 C0574083
severe
3m Syndrome 2 C2752041
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria Type 2 C0574083
Chronic
3m Syndrome 2 C2752041
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria Type 2 C0574083
No
3m Syndrome 2 C2752041
No
Different transmission
Body System
3 Methylglutaconic Aciduria Type 2 C0574083
metabolic
3m Syndrome 2 C2752041
musculoskeletal
Same/different system
Category
3 Methylglutaconic Aciduria Type 2 C0574083
metabolic
3m Syndrome 2 C2752041
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-type-2-C0574083 and 3m-syndrome-2-C2752041 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria Type 2 C0574083 | 3m Syndrome 2 C2752041 | Discriminating power |
|---|---|---|---|
| Heart involvement | Cardiomyopathy or heart-muscle weakness may occur and can be clinically important. | Primary cardiac disease is not a described feature in the supplied data. | High |
| Growth pattern | Growth failure may occur but is not the defining presentation. | Severe short stature with characteristic skeletal and facial findings is central. | High |
| Infection tendency | Recurrent infections may accompany neutropenia or immune vulnerability. | Recurrent infection is not established as a core feature. | Moderate |
When to favor each condition
Choose 3 Methylglutaconic Aciduria Type 2 C0574083 when
Male infant or child with cardiomyopathy and muscle weakness
This combination fits the described mitochondrial and cardiac pattern better than a primary growth syndrome.
High
Unexplained recurrent infections with metabolic concern
Infection susceptibility supports consideration of Barth syndrome, pending laboratory and genetic confirmation.
Moderate
Elevated 3-methylglutaconic acid reported
This abnormal metabolite result points toward the named aciduria, but it is not itself a complete diagnosis.
High
Choose 3m Syndrome 2 C2752041 when
Severe proportionate short stature from early life
Marked growth impairment with skeletal features aligns with 3M syndrome 2.
High
Characteristic facial and skeletal findings without cardiac disease
The supplied phenotype is musculoskeletal and genetic rather than primarily metabolic.
Moderate
Family history suggesting autosomal inheritance
This may favor 3M syndrome 2 over X-linked Barth syndrome, but testing must confirm the gene.
Low
How key tests differ
| Test | 3 Methylglutaconic Aciduria Type 2 C0574083 | 3m Syndrome 2 C2752041 | Interpretation |
|---|---|---|---|
| Urine organic acid analysis | 3-methylglutaconic acid may be elevated; exact cutoff is not supplied. | No characteristic organic acid elevation is established here. | An abnormal result supports metabolic evaluation but requires clinician and genetic correlation. |
| Echocardiography | May show cardiomyopathy or reduced heart-muscle function. | No characteristic cardiac abnormality is described. | Cardiac findings strongly favor Barth syndrome when present. |
| Genetic testing | A pathogenic TAZ variant may confirm Barth syndrome. | A pathogenic OBSL1 variant may confirm 3M syndrome 2. | Gene results distinguish the conditions; interpretation belongs to a genetics clinician. |
Prognosis comparison
3 Methylglutaconic Aciduria Type 2 C0574083
- Outcome
- Potentially serious chronic course, especially through cardiac and infection complications; individual outcome varies.
- Factors
- Cardiac function, infection history, feeding or growth, and access to specialist care.
3m Syndrome 2 C2752041
- Outcome
- Chronic but generally described as moderate, dominated by short stature and skeletal effects.
- Factors
- Degree of growth impairment, skeletal complications, and supportive orthopedic care.
Time frame: Both begin early and are chronic; precise survival or milestone data are not established here.
Genetic confirmation, involved organs, complications, and individualized specialist management.
Complications comparison
| Complication | Presentation |
|---|---|
| Cardiac complication | Heart-muscle weakness can cause serious illness and needs specialist follow-up. Cardiac complication is not established from the supplied description. Do not infer prognosis or mortality from these sparse data. |
| Infection | Recurrent infections may occur and require prompt assessment. Infection risk is not described as characteristic. Prevention strategies should be individualized by clinicians. |
| Skeletal or growth complication | Growth may be affected, but skeletal dysplasia is not the defining issue. Short stature and skeletal changes may require orthopedic and growth monitoring. Management is supportive; no treatment dose is established here. |
Patient education highlights
- HighDifferent conditions
Similar names do not mean similar disease. One centers on mitochondria and heart; the other on growth and skeleton.
- HighWarning symptoms
Breathing difficulty, poor feeding, fainting, or frequent infections need urgent clinical advice, especially when Barth syndrome is suspected.
- MediumConfirmation
Laboratory abnormalities and physical features require genetic confirmation and should not be self-diagnosed.